Celosia Therapeutics raises A$2M
Celosia Therapeutics announced a Debt / Non-dilutive round of A$2M on 18 November 2026. The company operates in HealthTech and is based in Australia. It was founded by Dr Kathryn Sunn, CEO. Announced today.
Founder
Dr Kathryn Sunn
CEO, Celosia Therapeutics
LinkedIn not available
Outreach angles
- -Dr Kathryn Sunn leads Celosia, a Macquarie University spinout built on research by professors Lars Ittner and Yazi Ke.
- -In March, Celosia dosed the first participant in a phase 1b trial of its lead programme, CTx1000, in sporadic ALS.
- -Celosia won the maximum A$2M grant, the largest in the first round of the NSW Emerging Technology Commercialisation Fund, to develop a second MND gene therapy.
Signals
DebtDeep TechHealthcareRegulated Industry
Round details
Company: Celosia Therapeutics
Domain: celosiatherapeutics
Amount: A$2M
Stage: Debt / Non-dilutive
Industry: HealthTech
Country: Australia
Announced: 18 November 2026
Other HealthTech raises
Recently funded in Australia